Literature DB >> 11526256

Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter.

Y Ge1, R I Grossman, J K Udupa, J S Babb, L G Nyúl, D L Kolson.   

Abstract

PURPOSE: To determine the fractional brain tissue volume changes in the gray matter and white matter of patients with relapsing-remitting multiple sclerosis (MS) and to correlate these measurements with clinical disability and total lesion load.
MATERIALS AND METHODS: Thirty patients with relapsing-remitting MS and 25 healthy control subjects underwent magnetic resonance imaging. Fractional brain tissue volumes (tissue volume relative to total intracranial volume) were obtained from the total segmented gray matter and white matter in each group and were analyzed.
RESULTS: The fractional volume of white matter versus that of gray matter was significantly lower (-6.4%) in patients with MS (P <.0001) than in control subjects. Neither gray matter nor white matter fractional volume measurements correlated with clinical disability in the patients with MS.
CONCLUSION: Loss of brain parenchymal volume in patients with relapsing-remitting MS is predominantly confined to white matter. Analysis of fractional brain tissue volumes provides additional information useful in characterizing MS and may have potential in evaluating treatment strategies.

Entities:  

Mesh:

Year:  2001        PMID: 11526256     DOI: 10.1148/radiol.2203001776

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  23 in total

1.  Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis.

Authors:  Carsten Lukas; Horst K Hahn; Barbara Bellenberg; Jan Rexilius; Gebhard Schmid; Sebastian K Schimrigk; Horst Przuntek; Odo Köster; Heinz-Otto Peitgen
Journal:  Neuroradiology       Date:  2004-11-05       Impact factor: 2.804

Review 2.  Current and new directions in MRI in multiple sclerosis.

Authors:  Eric C Klawiter
Journal:  Continuum (Minneap Minn)       Date:  2013-08

Review 3.  MRI in rodent models of brain disorders.

Authors:  Aleksandar Denic; Slobodan I Macura; Prasanna Mishra; Jeffrey D Gamez; Moses Rodriguez; Istvan Pirko
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Authors:  A Petzold; M J Eikelenboom; G Keir; D Grant; R H C Lazeron; C H Polman; B M J Uitdehaag; E J Thompson; G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 5.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

6.  Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis.

Authors:  Yulin Ge; Robert I Grossman; James S Babb; Marcie L Rabin; Lois J Mannon; Dennis L Kolson
Journal:  AJNR Am J Neuroradiol       Date:  2002-09       Impact factor: 3.825

7.  A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis.

Authors:  A Prinster; M Quarantelli; R Lanzillo; G Orefice; G Vacca; B Carotenuto; B Alfano; A Brunetti; V Brescia Morra; M Salvatore
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

Review 8.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

Review 9.  Interventions for the prevention of brain atrophy in multiple sclerosis : current status.

Authors:  Marco Rovaris; Massimo Filippi
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

Authors:  Richard A Rudick; Jar-Chi Lee; Kunio Nakamura; Elizabeth Fisher
Journal:  J Neurol Sci       Date:  2008-12-19       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.